Real world evaluation of HIV-1 reservoir and resistance in virologically suppressed people after 52 weeks of treatment with long-acting cabotegravir + rilpivirine
- 4 July 2026
- journal article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (11) , 107907
Abstract
No abstract availableKeywords
Funding Information
- FP7 Coordination of Research Activities
This publication has 34 references indexed in Scilit:
- Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi processThe Lancet HIV, 2025
- Acceptability of long acting injectable antiretroviral therapy in people living with HIV at a large single centreScientific Reports, 2025
- Utilizing HIV Proviral DNA to Assess for the Presence of HIV Drug ResistanceClinical Infectious Diseases, 2025
- Virologic Failure and Emergent Integrase Strand Transfer Inhibitor Drug Resistance With Long-Acting Cabotegravir for HIV Treatment: A Meta-analysisClinical Infectious Diseases, 2024
- Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trialThe Lancet Infectious Diseases, 2024
- Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individualsJournal of Clinical Virology, 2023
- Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority StudyClinical Infectious Diseases, 2023
- Genotypic correlates of resistance to the HIV-1 strand transfer integrase inhibitor cabotegravirAntiviral Research, 2022
- Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR studyThe Lancet HIV, 2021
- Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variantsClinical Microbiology and Infection, 2016